Lung cancer combo shows promise in slowing disease progression
NCT ID NCT04765059
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 36 times
Summary
This study tests whether adding the targeted drug osimertinib to standard chemotherapy can help people with a certain type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) whose disease has gotten worse after initial osimertinib treatment. About 98 participants will receive either chemotherapy plus osimertinib or chemotherapy plus a placebo. The main goal is to see if the combination delays cancer growth or spread.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Silver Spring, Maryland, 20910, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Beijing, 100005, China
-
Research Site
Beijing, 100142, China
-
Research Site
Ganzhou, 341099, China
-
Research Site
Guangzhou, 510080, China
-
Research Site
Jinan, 250013, China
-
Research Site
Shenyang, 110001, China
-
Research Site
Tianjin, 300060, China
-
Research Site
Zhengzhou, 450008, China
-
Research Site
Berlin, 12351, Germany
-
Research Site
Cologne, 50937, Germany
-
Research Site
Cologne, 51109, Germany
-
Research Site
Hanover, 30625, Germany
-
Research Site
München, D-80336, Germany
-
Research Site
Beersheba, 84101, Israel
-
Research Site
Jerusalem, 9103102, Israel
-
Research Site
Jerusalem, 9112001, Israel
-
Research Site
Kfar Saba, 4428164, Israel
-
Research Site
Tel Aviv, 6423906, Israel
-
Research Site
Tel Litwinsky, 52621, Israel
-
Research Site
Florence, 50134, Italy
-
Research Site
Meldola, 47014, Italy
-
Research Site
Messina, 98158, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Padova, 35128, Italy
-
Research Site
Roma, 00168, Italy
-
Research Site
Terni, 05100, Italy
-
Research Site
Verona, 37124, Italy
-
Research Site
Alicante, 03010, Spain
-
Research Site
Barcelona, 08907, Spain
-
Research Site
Córdoba, 14004, Spain
-
Research Site
León, 24071, Spain
-
Research Site
Madrid, 28040, Spain
-
Research Site
Málaga, 29010, Spain
-
Research Site
Murcia, 30008, Spain
-
Research Site
Oviedo, 33011, Spain
-
Research Site
Palma de Mallorca, 07010, Spain
-
Research Site
Seville, 41013, Spain
-
Research Site
Valencia, 46010, Spain
Conditions
Explore the condition pages connected to this study.